(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 107.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Plus Therapeutics's revenue in 2026 is $5,213,000.On average, 7 Wall Street analysts forecast PSTV's revenue for 2026 to be $40,492,827, with the lowest PSTV revenue forecast at $26,899,150, and the highest PSTV revenue forecast at $81,417,962. On average, 7 Wall Street analysts forecast PSTV's revenue for 2027 to be $146,373,919, with the lowest PSTV revenue forecast at $67,247,874, and the highest PSTV revenue forecast at $201,743,623.
In 2028, PSTV is forecast to generate $334,091,557 in revenue, with the lowest revenue forecast at $270,130,594 and the highest revenue forecast at $396,282,117.